LXRX

#2649
Lexicon Pharmaceuticals, Inc.
1.76 USD
+2.92%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
1.74
1.77
Year Range
0.48
1.84
Daily Change
+2.92%
Monthly Change
+3.53%
6 month change
+18.12%
Year Change
+232.08%
Previous Close
1.71
Open
1.75
Bid
Ask
Low
1.74
High
1.77
Volume
122
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 745.68 M
  • Employee 81
  • Founded 1995
  • CEO Lonnel Coats
  • Website www.lexpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG000BQ85G2
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-8.21
Price to sales ratio
8.38

Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.

News